IFNG and cancer: Janetzki et al showed that immunization with 25 μg of HSPPC-96 elicited MHC Class I-restricted, tumor-specific CD8+ T lymphocytes in 6 of 12 patients with advanced cancer using the IFNγ ELISPOT assay [7].